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INTRODUCTION
Radical hysterectomy and pelvic lymphadenectomy has
been widely accepted as the primary surgical modality for
the treatment of early stage cervical cancer. Pelvic node invol-
vement, which is known as one of the most important prog-
nostic factors, is detected in only 10-35% of patients with
early stage cervical cancer (1-3). Most pelvic lymph nodes
are dissected unnecessarily as the only method for detecting
metastasis. Pelvic lymphadenectomy can cause complications
such as vessel injury, nerve injury, lymphocyst and adhesion
formation (4). An accurate method, that could reflect the sta-
tus of the entire lymphatic area, without removing all lymph
nodes would spare patients the loss of unaffected lymph nodes
and give the chance of radical hysterectomy without lym-
phadenectomy; whereas patients with affected nodes would
be treated with chemoradiation. 
The sentinel lymph node (SN) is the first node draining
the lymphatic flow from a primary tumor, and represents the
status of lymphatic spread (5). SN biopsy is a standard treat-
ment modality in patients with cutaneous melanoma (6). If
this concept of SN biopsy could be applied to women with
cervical cancer, pelvic lymphadenectomy may not be needed
in patients who have SN results with no tumor cells on frozen
section at surgery. Previous studies have used different tech-
niques to identify the SN, which must be not only accurate
and reliable but also safe and easy to assess (5-17). One of
the widely used materials for detection, has been blue dye;
this method has been shown to be easy for physicians and
safe for patients; however, the SN detection rate is low and
anaphylactic reactions have been reported.
We used isosulfan blue dye, in relatively small amounts
(1% lymphazurin 2 mL) compared to other studies, to deter-
mine the feasibility and SN detection rate in patients with
early cervical cancer. 
MATERIALS AND METHODS
Between January 2003 and December 2003 eighty nine
patients underwent radical hysterectomy and pelvic lympha-
denectomy, primarily by laparotomy or laparoscopy, for early
stage cervical cancer all of whom were enrolled. 
After the induction of general anesthesia, the uterine cervix
was exposed with a speculum in the dorsolithotomy position.
Using a syringe with a 25-guage spinal needle, 1 mL of iso-
sulfan blue dye was injected into the cervix at the three and
nine o’clock orientation. After injection of the dye, disinfec-
tion was performed and subsequently the patient was tow-
eled. The abdominal cavity and the retroperitoneum were
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Detection of Sentinel Lymph Nodes in patients with Early Stage 
Cervical Cancer
The purpose of this study was to determine the feasibility of identifying the sentinel
lymph nodes (SNs) as well as to evaluate factors that might influence the SN detec-
tion rate in patients with cervical cancer of the uterus. Eighty nine patients underwent
intracervical injection of 1% isosulfan blue dye at the time of planned radical hysterec-
tomy and lymphadenectomy between January 2003 and December 2003. With the
visual detection of lymph nodes that stained blue, SNs were identified and removed
separately. Then all patients underwent complete pelvic lymph node dissection and/
or para-aortic lymph node dissection. SNs were identified in 51 of 89 (57.3%) patients.
The most common site for SN detection was the external iliac area. Metastatic nodes
were detected in 21 of 89 (23.5%) patients. One false negative SN was obtained.
Successful SN detection was more likely in patients younger than 50 yr (p=0.02)
and with a history of preoperative conization (p=0.05). However, stage, histological
type, surgical procedure and neoadjuvant chemotherapy showed no significant dif-
ference for SN detection rate. Therefore, the identification of SNs with isosulfan
blue dye is feasible and safe. The SN detection rate was high in patients younger
than 50 yr or with a history of preoperative conization.
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opened, taking care not to disturb the vessels and lymphat-
ics. Under direct visualization, the blue colored lymphatic
channels were identified (Fig. 1). All blue colored nodes were
considered SNs. All surgically removed lymph nodes includ-
ing SNs were sent for frozen section. If the pelvic lymph nodes
were negative, radical hysterectomy was performed. When
tumor cell was found in the frozen section, hysterectomy was
not performed but rather para-aortic lymphadenectomy was
done to determine the boundaries for radiation after surgery.
Surgical specimens were examined using routine hematoxylin
and eosin staining. 
To determine the important factors influencing the SN
detection rate, we dichotomized the variables (patient age,
FIGO stage, histopathology of tumor, preoperative coniza-
tion and neoadjuvant chemotherapy and status of SN) and
applied the chi-square test in dBSTAT 4.0.
RESULTS 
There was no adverse reaction associated with the isosulfan
dye injection such as: urticaria, edema, circulatory collapse
or respiratory problems. The mean age of patients was 48.3
yr (range 30-78). FIGO stage Ib1 was the most common
stage (54/89, 60.6%). The most common histological type
of tumor was a squamous cell carcinoma (61/89, 68.5%).
Preoperative conization was performed in 30 patients (33.7
%) and neoadjuvant chemotherapy in 24 patients (27.0%)
(Table1). 
Out of 89 patients, 83 SNs were detected in 51 (57.3%)
patients. The most common site for the SN was the external
iliac area; no SN was found in the para-aortic area. In 21 (23.5
%) patients, surgically removed lymph nodes were patholog-
ically proven to be positive. Among 51 patients in whom
SNs were detected, 11 (21.5%) patients were positive for
tumor cells (Table 2). 
The patients were grouped according to age (<50 yr vs. ≥
50), stage (below Ib1 vs. above Ib2), pathology (squamous
cell carcinoma vs. others), preoperative conization and neoad-
juvant chemotherapy. The detection rate of SNs was com-
pared among the dichotomized variables, and was found to
be high in patients younger than 50 yr or with a history of
preoperative conization (Table 3). 
The results of the frozen section were identical to those of
the permanent staining. The positive predictive value (PPV,
100%, 10/10), sensitivity (90.9%, 10/11), and specificity
(100%, 40/40) were assessed by comparing the status of SNs
with the status of all lymph nodes. The negative predictive
value (NPV) was 97.6% (40/41); this was because a non-col-
ored lymph node, from only one patient, contained tumor
cells with a negative SN (Table 4). 
The SN detection rate was 53.3% in 43 patients recruited
Fig. 1. Identification of a sentinel lymph node (arrow) stained with
blue dye after entering the retroperitoneal space. 
Characteristics No. of patients (%)
Mean age (range) 48.3 yr (30-78)
Stage
Ia2 4 (4.5)
Ib1 54 (60.6)
Ib2 15 (16.9)
IIa 11 (12.4)
IIb 5 (5.6)
Histology
Squamous cell carcinoma 61 (68.5)
Adeno carcinoma 17 (19.1)
Adenosquamous carcinoma 8 (9.0)
Small cell carcinoma 2 (2.3)
Mixed* 1 (1.1)
Prior conization
Yes 30 (33.7)
No 59 (66.3)
Neoadjuvant chemotherapy
Yes 24 (27.0)
No 65 (73.0)
Table 1. Clinical characteristics
*Adenosquamous and clear cell type. 
SN detection 51/89 cases (57.3%)
Number of SN 83
Localization of SN
External iliac 49 (59.0%)
Interanl iliac 9 (10.9%)
Obturator 24 (28.9%)
Common iliac 1 (1.2%)
LN metastasis 21/89 cases (23.5%)
SN metastasis 11/51 cases (21.5%)
Table 2. The localization and status of the sentinel lymph node
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during the first six months and 60.9% in 46 patients rec-
ruited during the last six months of the study period. The
difference was not statistically significant (Table 5). 
DISCUSSION 
Since 1977 when Cabanas introduced the SN concept, in
the treatment of penile carcinoma, SN detection has been
accepted as a standard diagnostic method for breast cancer
and melanoma. It has also been applied to gynecologic can-
cers (5, 7-15).
Dye application to map a SN does not require new equip-
ment and is relatively easy to learn. However, there are sev-
eral drawbacks including a low detection rate and anaphy-
lactic reaction. Multiple factors such as dosage, depth of dye
injection, type of marker used, tumor size and elapsed time
between administration of the dye and detection can influ-
ence the rate of SN detection (9-13, 21-23). Echt et al., pio-
neers in SN mapping for cervical cancer, injected 2 mL of
lymphazurin and detected the SN in 15.4% of patients (9).
Dargent et al. succeeded in detecting the SN in 85.5% (59/
69) of patients and confirmed that the detection rate improved
with increased amounts of dye (50%:<1.5 mL, 83%:2 mL,
90%:4 mL) (11). 
We injected 1% isosulfan blue 2 mL (Lymphazurin) at three
and nine o’clock orientations of the cervix (1 mL per each site)
and detected SN in 57.3% (51/89) of patients. The low detec-
tion rate might be due to the small amount of dye used to
prevent the occurrence of an anaphylactic reaction. 
Previous studies reported that an anaphylactic reaction
developed in 1-2% of breast cancer or melanoma patients
and showed a dose-response relationship (16, 17). In patients
with cervical cancer, 10% (1/10) of patients injected with
high density patent blue dye (2.5%, 0.2 mL) have been re-
ported to develop an anaphylactic reaction (15). With Lym-
phazurin (1% isosulfan blue) 4 mL, 5% (1/20) of patients
had circulatory collapse and 15% (3/20) experienced oxygen
desaturation measured by pulse oximetry (18). In our study,
only temporary low oxygen saturation was noted in a few
patients without clinical consequence.
Our results have confirmed the results of previous studies
in which SNs were detected at the external iliac, obturator,
internal iliac, and common iliac nodes in descending order
(19). Some authors have found SNs in the para-aortic area
but only concomitantly with pelvic nodes (10). We did not
detect SN in the extra-pelvic area.
SN detection in patients with cervical cancer, even if sus-
pected metastasis occurs through multiple routes to various
areas such as the locations reported in our results, can be very
useful. However, the false negative (negative SN in the pres-
ence of positive non-SN nodes) rate must be very low, and
the SN easy to detect, then perhaps SN study can be intro-
duced for cervical cancer patients (11, 12).
We observed that one patient had metastatic nodes out of
41 patients with visible negative SNs. The negative predic-
tive value was therefore 97.5% (40/41) in our study. Previous
studies have reported only four false negative cases out of 447
patients involved in SN mapping in patients with cervical
cancer. In other words the false negative rate was about 1%
(20).
In our study, SN detection rate was high only in patients
over 50 yr or in those with a history of preoperative coniza-
tion. Stage, histologic type of tumor or performance of neoad-
juvant chemotherapy was not associated with SN detection.
Dargent et al. reported that the SN detection rate, of patients
with preoperative conization, was 74%; this was lower than
that of patients without preoperative conization (86%); they
also reported that detection failure was not influenced by age,
stage, BMI or pathology (24).
O’Boyle et al. reported that care must be taken to estimate
Covariates
No. of 
patients (%)
Detection
rate of SN
p-
value
Age (yr)
<50 51 (57.3%) 68.6% 0.02
≥50 38 (42.7%) 42.1%
Stage
Ia2, Ib1 58 (65.2%) 60.3% NS
Ib2, IIa, IIb 31 (34.8%) 51.6%
Histology
Squamous 61 (68.5%) 54.1% NS
Non-squamous 28 (31.5%) 64.3%
Prior conization
Yes 30 (33.7%) 73.3% 0.05 
No 59 (66.3%) 49.1%
Neoadjuvant chemotherapy
Yes 24 (27.0%) 66.7% NS
No 65 (73.0%) 53.9%
Table 3. Factors affecting the detection rate of SNs
SN, Sentinel lymph node; NS, not significant. 
PLN 
metastasis (-)
PLN 
metastasis (+)
Total 
SN metastasis (-)4 0 1  4 1
SN metastasis (+) 0 10 10
Total 40 11 51    
Table 4. Relationship between the pathology of SNs and other
pelvic lymph nodes 
SN, Sentinel lymph node; PLN, Pelvic lymph node. 
Cases SN detection rate (%) p-value
Earlier half 23/43  53.5 NS
Later half 28/46  60.9
Table 5. Comparison of sentinel lymph node (SN) detection rate
between the first six months and the last six months
NS, Not significant.108 S.J. Seong, H. Park, K.M. Yang, et al.
the remnant volume of the cervix, and that it was easy to
cause intraperitoneal or rectal spillage (13). Preoperative
conization had no effect on the detection rate in their study.
In prior studies, investigators were more concerned about
the residual cervix after conization as a volumetric structure
rather than as a histologic tissue where dye flow might change
(11-13). Our data may stimulate future study on the impact
of preoperatvie conization; which may be a more important
factor than the dye injection method. 
In previous studies on patients with cervical cancer, there
has been no correlation noted between the patient’s age and
the SN detection rate. The cause of a low detection rate in
patients over 50 yr may result from decreased lymphatic flow
resulting from the aging process. Age and physician’s expe-
rience are known to be important factors influencing the SN
detection rate in breast cancer patients. As women get older,
fatty tissue in the mammary gland increases and lymphatic
flow lessens. An increase in the age of one year or one unit of
BMI decreases the odds of success for SN detection by 5% (21).
The learning curve for laparoscopic retrieval of SN showed
that the average time from injection to retrieval of the first
node was shorter with time (24). Attending physicians with
experience in lymphatic mapping of vulvar cancer, a short
learning curve has been observed (12). In our study, laparo-
tomic or laparoscopic SN detection was performed accord-
ing to the preference of surgeons who had experience with
radical surgery. The detection rate was similar between the
first 43 patients and the last 46 patients, which suggested
the need for a very short learning period. If physicians are
accustomed to radical surgery, lymphatic mapping with blue
dye and detection of SNs are relatively easy to learn. 
Limitations of this study include the following: we did
not consider time elapsed, tumor size and depth of injection;
which were important factors noted in previous studies. This
could have lowered our detection rate.
In conclusion, SN detection, with a small amount of iso-
sulfan blue dye (1% Lymphazurin 2 mL) is feasible and safe;
however, our results show a low detection rate. Age and his-
tory of preoperative conization are important factors influ-
encing the success rate of SN detection; which was higher
in patients younger than 50 yr or with a history of preoper-
ative conization. 
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